131,332 Shares in Oculis Holding AG $OCS Acquired by Alyeska Investment Group L.P.

Alyeska Investment Group L.P. purchased a new position in shares of Oculis Holding AG (NASDAQ:OCS) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 131,332 shares of the company’s stock, valued at approximately $2,499,000. Alyeska Investment Group L.P. owned about 0.30% of Oculis as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Bank of America Corp DE increased its position in Oculis by 58.2% during the fourth quarter. Bank of America Corp DE now owns 28,980 shares of the company’s stock worth $493,000 after purchasing an additional 10,667 shares during the last quarter. Citadel Advisors LLC acquired a new position in Oculis during the fourth quarter worth approximately $389,000. Kestra Private Wealth Services LLC acquired a new position in Oculis during the first quarter worth approximately $234,000. Aberdeen Group plc increased its position in Oculis by 24.1% during the first quarter. Aberdeen Group plc now owns 1,253,119 shares of the company’s stock worth $23,847,000 after purchasing an additional 243,695 shares during the last quarter. Finally, Pivotal bioVenture Partners Investment Advisor LLC increased its position in Oculis by 32.4% during the first quarter. Pivotal bioVenture Partners Investment Advisor LLC now owns 2,300,774 shares of the company’s stock worth $43,784,000 after purchasing an additional 563,078 shares during the last quarter. Institutional investors and hedge funds own 22.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on OCS shares. Needham & Company LLC assumed coverage on shares of Oculis in a research report on Wednesday, August 27th. They set a “buy” rating and a $36.00 price target for the company. Chardan Capital boosted their price objective on shares of Oculis from $28.00 to $33.00 and gave the stock a “buy” rating in a research note on Friday, May 9th. Finally, HC Wainwright boosted their price objective on shares of Oculis from $32.00 to $33.00 and gave the stock a “buy” rating in a research note on Friday, August 22nd. Four research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $35.75.

Oculis Price Performance

OCS opened at $17.22 on Friday. The company has a market cap of $751.86 million, a P/E ratio of -6.45 and a beta of 0.26. The company has a 50 day moving average of $17.85 and a two-hundred day moving average of $18.37. The company has a quick ratio of 4.55, a current ratio of 4.55 and a debt-to-equity ratio of 0.01. Oculis Holding AG has a 52-week low of $11.56 and a 52-week high of $23.08.

Oculis (NASDAQ:OCS) last announced its earnings results on Thursday, August 21st. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.06). The firm had revenue of $0.25 million during the quarter, compared to analysts’ expectations of $0.14 million. Oculis had a negative net margin of 13,958.12% and a negative return on equity of 90.31%. On average, analysts expect that Oculis Holding AG will post -2.09 earnings per share for the current year.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.